Fortress Biotech, Inc. (FBIO)

Market Cap	54.11M
Revenue (ttm)	57.78M
Net Income (ttm)	-50.75M
Shares Out	29.57M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,167
Open	1.820
Previous Close	1.820
Day's Range	1.764 - 1.859
52-Week Range	1.325 - 2.890
Beta	1.77
Analysts	Strong Buy
Price Target	21.00 (+1,047.54%)
Earnings Date	Aug 12, 2025

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: FBIO
• Website: https://www.fortressbiotech.com

Financial Performance

In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 1,047.54% from the latest price.

Price Target

$21.0

(1,047.54% upside)

Analyst Consensus: Strong Buy